Optimizing iron chelation strategies in β-thalassaemia major

This publication has 21 references indexed in Scilit:

• Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia
  European Journal of Haematology, 2009
• Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
  Journal of Cardiovascular Magnetic Resonance, 2009
• Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major
  Blood, 2008
• Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload
  Annals of Hematology, 2006
• Deferiprone or Deferoxaminevs. Combination Therapyin Patients with β-Thalassemia Major: A Case Studyin Taiwan
  Hemoglobin, 2006
• Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators
  Hemoglobin, 2006
• Deferiprone: New Insight
  Annals of the New York Academy of Sciences, 2005
• LPI-labile plasma iron in iron overload
  Best Practice & Research Clinical Haematology, 2005
• Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
  British Journal of Haematology, 2003
• Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
  European Heart Journal, 2001